Author:
Hernandez Inmaculada,Zhang Yuting
Funder
La Caixa Foundation
Commonwealth Fund
Agency for Healthcare Research and Quality
National Institute of Mental Health
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cardiology and Cardiovascular Medicine,General Medicine
Reference32 articles.
1. Ridgefield CT. Pradaxa prescribing information. Boehringer Ingelheim Pharmaceuticals. 2015. Available from:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s028lbl.pdf
. Accessed 12 Jan 2016.
2. Titusville NJ. Prescribing information for Xarelto. Janssen Pharmaceuticals, Inc. 2015.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022406s012lbl.pdf
. Accessed 14 May 2015.
3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.
4. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.
5. Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC, et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol. 2014;63(9):891–900.